On the 7th of August 2014, Tekmira Pharmaceuticals Announced That the FDA has Allowed Potential Use of Their Experimental Ebola Drug on Infected Patients

FDA Modifies Tekmira’s TKM-Ebola Clinical Hold to Partial Hold

August 7th, 2014 -FDA Modifies Tekmira’s TKM-Ebola Clinical Hold to Partial Hold -Enabling Use of Tekmira’s Investigational Therapeutic in Ebola-Infected Patients ekmira Pharmaceuticals Corporation (TKMR) (TKM.TO), a leading developer of RNA interference (RNAi) therapeutics, today announced that the U.S. Food & Drug Administration (FDA) has verbally confirmed they have modified the full clinical hold placed on the TKM-Ebola Investigational New …